India's MedTech and Pharma Boom Signals Shift to Self-Reliant Healthcare Growth
Union Minister of State for Science and Technology, Jitendra Singh, has declared that India is steadily evolving into a robust pharma economy. He emphasized that this transformation will accelerate future growth and emerge as a significant contributor to the country's overall GDP.
Key Global Hub for Affordable Healthcare
Delivering a keynote address at a healthcare summit in New Delhi, Singh highlighted that the growing strength of India's pharmaceutical and medtech manufacturing ecosystem positions the nation as a key global hub for affordable healthcare solutions. He explained that the national healthcare ecosystem is undergoing a major shift, focusing on global quality benchmarks and the integration of research with industry.
From Import-Dependence to Indigenous Capabilities
Singh noted that over the past decade, India has witnessed a remarkable transformation in healthcare, moving from a largely import-dependent system to one driven by indigenous capabilities. He recalled a time when critical medical devices, implants, and advanced drugs were largely sourced from abroad, making treatment expensive and inaccessible for many citizens.
"Today, India is developing its own antibiotics, vaccines, and advanced therapies, marking a decisive shift towards self-reliance," Singh said. He referred to the rapid progress made during the COVID-19 pandemic as a turning point, where India supplied vaccines to several countries, reinforcing its role as a global healthcare partner.
Cutting-Edge Technologies and Research
The narrative of the sector now includes cutting-edge technologies such as gene therapy and innovations for diseases like sickle cell anemia. Singh pointed out that Indian institutions now contribute to globally recognized research, with homegrown products matching global benchmarks. Regulatory systems are aligned to international standards, and through streamlined approval mechanisms, indigenous medical devices such as stents and ventilators are ensuring safety and affordability.
Policy Initiatives Driving Innovation
On the policy front, Singh highlighted the Promotion of Research and Innovation in Pharma-MedTech (PRIP) scheme, which has an outlay of Rs 5,000 crore. This initiative aims to transition India from low-cost manufacturing to high-value innovation. He also mentioned the MedTech Mitra platform, which is enabling innovators to navigate regulatory pathways more efficiently.
Expanding Global Market Share
Currently, India holds approximately 1.5 per cent of the global medical device market. However, Singh stated that the government is working to significantly expand this share under the National Medical Device Policy 2023. He emphasized that collaboration between industry, academia, and government institutions has been institutionalized to ensure India becomes a preferred global destination for high-quality healthcare.
This development underscores India's strategic move towards self-sufficiency in healthcare, leveraging its medtech and pharma sectors to boost economic growth and global influence.
